The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Dec. 24, 2024

Filed:

Oct. 18, 2019
Applicant:

Merck Patent Gmbh, Darmstadt, DE;

Inventors:

Giorgio Massimini, Darmstadt, DE;

Ilhan Celik, Zwingenberg, DE;

Josef Straub, Seeheim-Jugenheim, DE;

Rolf Bruns, Darmstadt, DE;

Rita Laeufle, San Diego, CA (US);

Assignee:

Merck Patent GmbH, Darmstadt, DE;

Attorney:
Primary Examiner:
Assistant Examiner:
Int. Cl.
CPC ...
A61K 39/395 (2006.01); A61K 31/44 (2006.01); A61K 31/4745 (2006.01); A61K 31/513 (2006.01); A61K 31/519 (2006.01); A61K 31/7072 (2006.01); A61K 33/243 (2019.01); A61K 38/17 (2006.01); A61K 39/00 (2006.01); A61P 35/00 (2006.01); C07K 16/22 (2006.01); C07K 16/28 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39558 (2013.01); A61K 31/44 (2013.01); A61K 31/4745 (2013.01); A61K 31/513 (2013.01); A61K 31/519 (2013.01); A61K 31/7072 (2013.01); A61K 33/243 (2019.01); A61K 38/179 (2013.01); A61P 35/00 (2018.01); C07K 16/22 (2013.01); C07K 16/2848 (2013.01); C07K 16/2863 (2013.01); A61K 2039/505 (2013.01); A61K 2039/507 (2013.01); A61K 2039/545 (2013.01); C07K 2317/76 (2013.01);
Abstract

Methods of treatment of colorectal cancer can include the administration of the anti-alpha-v integrin (receptor) antibody Abituzumab. Preferably, the methods of treating colorectal cancer can include treating Stage II-IV colorectal cancer, metastatic colorectal cancer, left-sided colorectal cancer and/or left-sided metastatic colorectal cancer, involving the administration of said Abituzumab to patients in need thereof. Abituzumab is also useful for the manufacture of a medicament for treating colorectal cancer, preferably colorectal cancer as defined herein. Abituzumab is further useful for the manufacture of a medicament for treating colorectal cancer in combination with suitable targeted therapy concepts, such as growth factor or growth factor receptor targeting monoclonal antibodies, and/or chemotherapy.


Find Patent Forward Citations

Loading…